Do you want to link to our other external sites and leave Amgen.ca?
You are now leaving the Amgen Canada website. Please note that the information you are about to view may not comply with Canadian regulatory requirements. Marketing authorizations and availability of products may differ between Canada and other countries.
You are now leaving the Amgen.ca website.
The linked sites are not under the control of Amgen, and Amgen is not responsible for the content available on the linked sites. Such links do not imply Amgen's endorsement of material on any other site, and Amgen disclaims all liability with regard to your access to such linked websites. Amgen provides links to other Internet sites as a convenience to users, and access to such linked sites is at your own risk
Amgen's drugs target diseases that are serious and typically have limited treatment options.
With a presence in more than 100 countries, every year we reach millions of patients around the world.
At Amgen we take advantage of the full potential of biotechnology to collaborate and provide new tools for clinical practice. In Canada, we focus on the following therapeutic areas:
Amgen has a portfolio of innovative products and biosimilars for the treatment of oncological and hematological diseases, such as non-small cell lung cancer, colorectal cancer, and acute lymphoblastic leukemia, among others.
Amgen developed medicines in the field of inflammation, and we are currently discovering innovative molecules to treat chronic inflammatory diseases. Some of the conditions to which we provide solutions are for autoimmune pathologies such as rheumatoid arthritis and psoriasis, which affect millions of patients in the world. Inflammation is another field in which Amgen has biosimilars approved to improve healthcare costs in chronic diseases.
Amgen is a leader in bone health with more than 20 years of osteoporosis research experience, and is committed to combating this disease to help people at high risk for fracture reduce their risk of a first and subsequent fracture.
Amgen is dedicated to addressing important scientific questions to advance care and improve the lives of patients with cardiovascular disease, the leading cause of morbidity and mortality worldwide.